Associations of serum peroxisome proliferator-activated receptor-γ coactivator-1α with cerebral microbleeds and their severity in patients with cerebral small vessel disease
10.3760/cma.j.issn.1673-4165.2024.05.005
- VernacularTitle:血清过氧化物酶体增殖物激活受体γ辅助活化因子-1α与脑小血管病患者脑微出血及其严重程度的相关性
- Author:
Pei XU
1
;
Xiangyang ZHU
Author Information
1. 南通大学医学院，南通 226001
- Keywords:
Cerebral small vessel diseases;
Cerebral hemorrhage;
Magnetic resonance imaging;
Peroxisome proliferator-activated receptor γ coactivator 1-α
- From:
International Journal of Cerebrovascular Diseases
2024;32(5):344-348
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate associations of serum peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) with cerebral microbleeds (CMBs) and their severity in patients with cerebral small vessel disease (CSVD).Methods:Consecutive patients with CSVD admitted to the Department of Neurology, the Second Affiliated Hospital of Nantong University and the Eighth People's Hospital of Tongzhou District, Nantong from August 2022 to August 2023 were prospectively included. According to the MRI findings, patients were divided into non-CMB group and CMB group, with the latter further divided into mild CMB group (1-2), moderate CMB group (3-10), and severe CMB group (>10). Multivariate logistic regression analysis was used to identify the independent correlation factors of CMBs. Multiple linear regression analysis was used to identify the correlation between serum PGC-1α and the number of CMBs. Results:A total of 158 patients with CSVD were included, of which 96 (60.8%) had CMBs; among them, 55 patients had mild CMBs, 24 had moderate CMBs, and 17 had severe CMBs. The PGC-1α and white blood cell count in the CMB group were significantly lower than those in the non-CMB group, while age, platelet count, triglycerides, fasting blood glucose, and glycated hemoglobin were significantly higher than those in the non-CMB group (all P<0.05). Multivariate logistic regression analysis showed that after adjusting for the confounding variables such as age, fasting blood glucose, and white blood cell count, PGC-1α was an independent protective factor for CMBs in patients with CSVD (odds ratio 0.588, 95% confidence interval 0.415-0.833; P=0.003). Multiple linear regression analysis showed a significant negative correlation between serum PGC-1α and the number of CMBs ( β=-0.566, P<0.001). Conclusion:Serum PGC-1α is associated with CMBs and their severity in patients with CSVD; the higher the serum PGC-1α, the lower the likelihood of the presence of CMBs.
